40-Year Pharma Veteran To Lead Aseptic Fill & Finish Startup
Mr. Novak brings to Salubrent over four decades of business development, operational and executive experience in the pharmaceutical, biotech, and CDMO industries. He has held senior leadership positions in numerous CDMOs, including DSM Pharmaceuticals, Patheon, and Norwich. Over his career he has managed P&Ls up to $250 mm and spearheaded due diligence and contract negotiations resulting in over $800 mm in acquisitions and contract service agreements.
During his career, Mr. Novak has successfully grown four CDMOs by developing strong relationships with key decision-makers at pharma and biotech companies and by ensuring high-quality, metrics-driven customer service and operational excellence. His track record includes achieving consistent double-digit growth in revenues and EBITDA for companies.
“Terry is perfect for Salubrent,” said Matt Berger, a partner at Minutemen Life Sciences, the parent company of Salubrent. “In his career, he’s taken on important roles at some amazing companies, but there’s always been one constant: his incredible ability to create meaningful relationships between stakeholders, and then leverage those relationships to everyone’s benefit. We’re delighted he’s going to bring that talent to Salubrent.”
“I couldn’t be happier to join the most exciting new company in the CDMO industry,” added Terry Novak, the company’s new Chairman & CEO. “Salubrent is the future of fill & finish development and manufacturing, and with our flexible aseptic solutions we’ll be doing our part to ensure that patients’ live that will be improved while helping secure our nation’s drug supply.”
ABOUT SALUBRENT PHARMA SERVICES
Salubrent Pharma Solutions is a full-service CDMO offering analytical services to clinical and commercial stage pharma and biotech companies. Founded by industry veterans with over 200 years of combined industry experience, Salubrent provides clinical and commercial stage pharma and biotech companies with the expertise needed to successfully bring their products to the clinic and eventually the market. Salubrent will soon begin construction on the first of four US-based aseptic fill-finish facilities, each located in a major biotech hub and focusing on personalized medicine and PI/II CTM batches for those companies in need of small batch production of sterile injectable products.. Analytical services will be available in 2021, with proof-of-concept commercial aseptic services launching in 2022.
Learn more at salubrent.com